加载中
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
前收盘价
US$4.87
US$0.00 · 0.00%
盘后
US$4.87
US$0.00 · 0.00%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
日内区间
当前US$4.87
52周区间
当前US$4.87
盘中时间采用ET。市场数据可能有所延迟。
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
日内区间
当前US$4.87
52周区间
当前US$4.87
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 销货成本 | 3.1万 USD | — | — | — | — |
| 毛利 | −3.1万 USD | — | — | — | — |
| 研究与开发 | 5379.8万 USD | 6152.7万 USD | 5574.3万 USD | 4381.3万 USD | 3248.6万 USD |
| 销售、一般及管理费用 | 2916.8万 USD | 1836.7万 USD | 1468万 USD | 1217.7万 USD | 935.7万 USD |
| 营业费用 | 8296.6万 USD | 7989.4万 USD | 7042.3万 USD | 5599万 USD | 4184.3万 USD |
| 利息收入 | 488万 USD | 548.2万 USD | 487万 USD | 420.8万 USD | 8万 USD |
| 利息支出 | — | — | — | — | 180.7万 USD |
| 折旧和摊销 | 3.1万 USD | 3.1万 USD | 3.6万 USD | 3万 USD | 1.3万 USD |
| 营业利润 | −8296.6万 USD | −7989.4万 USD | −7042.3万 USD | −5599万 USD | −4184.3万 USD |
| 净利润 | −7758.6万 USD | −7441.2万 USD | −6845.9万 USD | −5178.7万 USD | −4106万 USD |
公司数据更新于 2026年10月13日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$9.17
上涨空间 88.30%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1287.24万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM1019.67万0.01%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF477.29万0.00%954亿 USD0.05%US$233.52-0.63%
Dimensional - US Small Cap ETFDFAS232.4万0.01%338.69亿 USD0.31%US$78.17-0.23%
Vanguard Russell 2000 ETFVTWO211.14万0.01%180亿 USD0.06%US$112.27-0.35%
Schwab U.S. Small-Cap ETFSCHA198.49万0.01%218.24亿 USD0.03%US$32.66-0.40%
Fidelity Enhanced Small Cap ETFFESM188.06万0.03%64.1亿 USD0.28%US$45.24-0.48%
Janus Henderson Small Cap Growth Alpha ETFJSML124.06万0.34%3.61亿 USD0.30%US$86.7888-0.79%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFDimensional - US Small Cap ETFDFASVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAFidelity Enhanced Small Cap ETFFESMJanus Henderson Small Cap Growth Alpha ETFJSMLAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
